It looks like you are using an outdated browser which may lead to usability issues.
We highly encourage you adopt a modern browser before proceeding.
Click here
Clinical Connection
A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin Lymphoma (HL) in patients with significant comorbidities who are ineligible to be treated with standard chemotherapy